Giuseppe Ferrante, Patrizia Presbitero, Paolo Pagnotta, Anna Sonia Petronio, Nedy Brambilla, Federico De Marco4, Claudia Fiorina, Cristina Giannini, Fabrizio D’Ascenzo, Silvio Klugmann, Marco L Rossi, Federica Ettori, Francesco Bedogni, Luca Testa. Impact of severe left ventricular dysfunction on mid-term mortality in elderly patients undergoing transcatheter aortic valve implantation[J]. Journal of Geriatric Cardiology, 2016, 13(4): 290-298. DOI: 10.11909/j.issn.1671-5411.2016.04.001
Citation: Giuseppe Ferrante, Patrizia Presbitero, Paolo Pagnotta, Anna Sonia Petronio, Nedy Brambilla, Federico De Marco4, Claudia Fiorina, Cristina Giannini, Fabrizio D’Ascenzo, Silvio Klugmann, Marco L Rossi, Federica Ettori, Francesco Bedogni, Luca Testa. Impact of severe left ventricular dysfunction on mid-term mortality in elderly patients undergoing transcatheter aortic valve implantation[J]. Journal of Geriatric Cardiology, 2016, 13(4): 290-298. DOI: 10.11909/j.issn.1671-5411.2016.04.001

Impact of severe left ventricular dysfunction on mid-term mortality in elderly patients undergoing transcatheter aortic valve implantation

  • Background Whether patients with reduced left ventricular function present worse outcome after transcatheter aortic valve implantation (TAVI) is controversial. The aim of this study was to assess the impact of baseline severe impairment of left ventricular ejection fraction (LVEF) on mortality after TAVI. Methods Six-hundred-forty-nine patients with aortic stenosis underwent TAVI with the CoreValve system (92.8%) or the Edwards SAPIEN valve system (7.2%). Baseline LVEF was measured by the echocardiographic Simpson method. The impact of LVEF ≤ 30% on mortality was assessed by Cox regression. Results Patients with LVEF ≤ 30% (n = 63), as compared to those with LVEF > 30% (n = 586), had a higher prevalence of NHYA class > 2 (P P vs. 97.2%, P = 1). After a median follow-up of 436 days (25th–75th percentile, 357–737 days), all-cause mortality 23.8% vs. 23.7%, P = 0.87, hazard ratios (HR): 0.96, 95% confidence intervals (CI): 0.56–1.63 and cardiac mortality (19.1% vs. 17.6%, P = 0.89, HR: 1.04, 95% CI: 0.57–1.90) were similar in patients with LVEF ≤ 30% as compared to those with LVEF > 30%. Thirty-day all-cause mortality was not significantly different between the two groups (11.1% vs. 6.3%, P = 0.14, HR: 1.81, 95% CI: 0.81–4.06). Patients with LVEF ≤ 30% had a trend toward higher risk of 30-day cardiac mortality (11.1% vs.5.3%; P = 0.06, HR: 2.16, 95% CI: 0.95–4.90), which disappeared after multivariable adjustment (P = 0.22). Conclusions Baseline severe impairment of LVEF is not a predictor of increased short-term and mid-term mortality after TAVI. Selected patients with severe impairment of left ventricular function should not be denied TAVI.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return